U.S. markets open in 7 hours 38 minutes
  • S&P Futures

    4,358.25
    +15.00 (+0.35%)
     
  • Dow Futures

    33,924.00
    +126.00 (+0.37%)
     
  • Nasdaq Futures

    15,060.50
    +36.50 (+0.24%)
     
  • Russell 2000 Futures

    2,190.10
    +9.20 (+0.42%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,778.90
    +0.70 (+0.04%)
     
  • Silver

    22.78
    +0.17 (+0.77%)
     
  • EUR/USD

    1.1727
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    24.36
    -1.35 (-5.25%)
     
  • GBP/USD

    1.3655
    -0.0010 (-0.07%)
     
  • USD/JPY

    109.5030
    +0.2830 (+0.26%)
     
  • BTC-USD

    41,968.72
    -494.19 (-1.16%)
     
  • CMC Crypto 200

    1,039.82
    -24.03 (-2.26%)
     
  • FTSE 100

    6,980.98
    +77.07 (+1.12%)
     
  • Nikkei 225

    29,706.52
    -133.19 (-0.45%)
     

Regeneron, AstraZeneca to develop obesity treatment

Regeneron, AstraZeneca to develop obesity treatment
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Regeneron Pharmaceuticals Inc. were down 0.1% in premarket trading on Tuesday after the company announced a deal with AstraZeneca to develop and commercialize obesity treatments that target a specific gene, GPR75. The companies will split development costs and profits if the drug is successful. Regeneron's stock is up 19.6% so far this year, while the S&P 500 has gained 17.7%.